Fig. 2From: Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary diseaseSurvival outcomes. A Progression-free survival (PFS) of all patients. B Overall survival (OS) of all patients. C PFS and OS of non-responders (N = 10) versus responders (N = 21)Back to article page